AVNS vs BAX
AVNS: Avanos Medical provides specialized medical device solutions for enteral nutrition and non-opioid pain management to improve patient recovery outcomes. BAX: Baxter International is a leading medical technology company delivering critical life-sustaining therapies for patients with complex medical conditions in hospitals and at home.
Side-by-side fundamentals
| Metric | AVNS | BAX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $24.99 | $23.90 | |
| Market cap | $1.2B | $12.4B | |
| Net margin FY2025, SEC XBRL | -10.4% | -8.5% | BAX higher |
| Gross margin FY2025, SEC XBRL | +50.5% | +30.1% | AVNS higher |
| Operating margin FY2025, SEC XBRL | -8.8% | -2.7% | BAX higher |
| ROE FY2025, SEC XBRL | -9.4% | -15.7% | AVNS higher |
| ROA FY2025, SEC XBRL | -6.8% | -4.8% | BAX higher |
| Debt / equity as of 2026-09-03 | 0.13 | 1.52 | AVNS lower |
| Revenue growth (YoY) as of 2026-09-03 | +3.9% | +5.4% | BAX higher |
| Revenue CAGR (3y) SEC XBRL | +0.8% | +3.8% | BAX higher |
| Dividend yield as of 2026-09-03 | n/a | +0.2% | |
| Dividend streak (yrs) SEC XBRL | 0 | 1 | BAX higher |
| Beta as of 2026-09-03 | 0.73 | 0.94 | |
| 1-year return as of 2026-10-08 close | +119.2% | +5.1% | AVNS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.